Biosimilar policy is the perfect example of what happens when the industry does not deliver constructively, with the government forced into policy responses like the disastrous 2023 catch-up statutory price reductions.
The terrible events of 2023 were born of a decade-old policy failure
March 11, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Queensland cardiac experts back a new plan to stop the second heart attack
September 18, 2026 - - Latest News -
We have one of Australia's answers to 'MFN' and people will die as a result
September 18, 2026 - - Latest News -
Is the fairest part of our medicines access system delivered overseas?
September 18, 2026 - - Latest News -
Mayne Pharma bets on an untapped corner of the menopause market
September 17, 2026 - - Latest News -
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News
